By the Top Tier Newswire AI Desk · September 22, 2026 at 11:19 AM ET · reviewed against 19 wire stories
MODERNA INC (MRNA) is up +7.12% in the latest session. Our newswire has captured 19 stories on MRNA across 15 sources in the last 36 hours, with AI sentiment reading bullish (avg 64/100).
Public view, delayed 4h. Every headline, price and sentiment read below — and this write-up itself — reaches Pro subscribers live. Public readers see it once it clears the delay.
Moderna Inc. (MRNA) surged 7.12% to $185.26 in a volatile session driven by anticipation of late-stage data for its personalized cancer therapy. The stock climbed following a series of announcements about upcoming presentations at the ESMO 2026 oncology congress, including a Phase 3 melanoma study set for October 24. The rally reflects investor optimism ahead of what could be a pivotal moment for the company’s intismeran autogene program.
What Happened
Moderna highlighted its Phase 3 melanoma data slot at ESMO 2026 and scheduled an investor webcast for October 24. The company also announced that three intismeran autogene abstracts were accepted for the ESMO Congress 2026, with a late-breaking study selected for a Presidential Symposium. These developments have intensified investor interest, particularly as UBS reiterated its rating on Moderna stock ahead of the melanoma data release. Meanwhile, retail traders on social platforms are highlighting the upcoming data as a potential catalyst, and the stock has hit a 52-week high for the first time this week.
What The Data Shows
The intraday session was marked by a sharp reversal after a -0.8% gap down open. The stock bottomed at $167.60 before rallying to a high of $187.20, closing near the session peak. Volume was 9.0 million shares, or 0.7 times the 3-month average, suggesting moderate participation. Over the past eight sessions, the stock has gained 23.4%, moving from $147.81 to $182.38. Unusual options activity has also been noted, with call premiums reaching $74.9 million compared to $7.2 million in puts. Recent insider transactions include five sales totaling $49.2 million, with no insider buys reported in the last 90 days.
What To Watch
The October 24 ESMO 2026 presentation is the key event to monitor. The data could provide clarity on the efficacy of Moderna’s melanoma therapy, potentially influencing the stock’s trajectory. Investors should also watch for any follow-up analyst commentary or changes in coverage following the data release.
AI-assisted analysis composed exclusively from headlines and data on the Top Tier newswire. Public view is delayed 4 hours from real time. Not financial advice.
MRNA · Sep 22 session (5-min) · +5.35% vs prior close · updated 8:56 PM ETAI sentiment, last 36h · averaged over 19 stories · 64/100 bullish
The headlines behind the move
Story flow · 8 stories on the wire, last 36h · hover or tap a dot for the headline
45d ago24/7 Wall St.BULLISH 78Earnings
Moderna Adds Another 5% and Is Up 500% in 2026. Can MRNA Stock Continue the Melt-Up?
Shares of Moderna (NASDAQ:MRNA) are rallying again as investors position ahead of a late-October data drop that could validate the first personalized cancer therapy tested at scale. Moderna stock is at $181.51, up 5% in Tuesday morning trading, and it is up 516% year to date (YTD). Broader biotech isn’t matching that pace. The iShares […]
45d agoThe Motley FoolBEARISH 42Analyst
Should You Buy Moderna Stock? Why Many Wall Street Analysts Say "No."
Following last month's super rally, a growing number of analysts are now calling for caution.
UBS reiterates Moderna stock rating ahead of melanoma data
UBS reiterates Moderna stock rating ahead of melanoma data
45d agoQuartzBULLISH 63Product/PR
How the Merck-Moderna mRNA melanoma vaccine is built per patient - qz.com
45d agoMarketChameleonBULLISH 67Product/PR
Moderna Highlights Phase 3 Melanoma Data Slot at ESMO 2026, Sets Oct. 24 Investor Webcast
September 22, 2026
Moderna said three intismeran autogene abstracts have been accepted for ESMO Congress 2026, led by a late-breaking Phase 3 melanoma study selected for a Presidential Symposium presentation on Oct. 24. The company also scheduled an investor webcast for later that same day, creating a defined timeline for investors tracking its individualized neoantigen therapy program across melanoma, pancreatic cancer, and early-stage NSCLC.
45d agoStocktwits NewsBULLISH 73General
Why Did AMD, WBD, MRNA Stocks Surge To 52-Week Highs Today?
Advanced Micro Devices, Warner Bros. Discovery and Moderna stocks surged to annual highs amid a series of positive catalysts.
45d agoSeeking AlphaBULLISH 55General
Stocks to watch on Monday after hours: MRNA, ARM, and PBF
Wall Street’s major averages closed firmly in the green Monday as investors awaited the upcoming Trump-Xi summit.
45d agoSeeking AlphaBULLISH 73Product/PR
Moderna rallies 12% to set new high
Moderna (MRNA) hits a new 52-week high on ESMO 2026 oncology data plans as intismeran buzz grows.
Want the next move before the crowd? The live terminal streams every headline in real time with watchlist alerts, AI sentiment, and the full data stack behind this page.Get Pro Access →